TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and safety to standard of care in BCG-unresponsive, non-muscle invasive bladder cancer, with intravesical administration that is already deployed in practices. TD expects the management team to successfully launch cretostimogene in 2026.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener